NCT02628600View on ClinicalTrials.gov

Open-label Safety Extension Study Assessing Safety and Tolerability of LAI in Patients Who Participated in Study INS-212

PHASE3CompletedINTERVENTIONAL
Enrollment

163

Participants

Timeline

Start Date

February 5, 2016

Primary Completion Date

October 17, 2018

Study Completion Date

October 17, 2018

Conditions
NTM Lung Infection Due to MAC
Interventions
DRUG

LAI 590 mg

LAI 590 mg QD: administered by inhaling drug product that had been aerosolized in an investigational eFlow nebulizer over approximately 14 minutes

DRUG

Multi-drug regimen

Multidrug antimycobacterial regimen from study INS-212

All Listed Sponsors
lead

Insmed Incorporated

INDUSTRY

NCT02628600 - Open-label Safety Extension Study Assessing Safety and Tolerability of LAI in Patients Who Participated in Study INS-212 | Biotech Hunter | Biotech Hunter